Welcome to the Settlement Website for the Teva Securities Litigation.

If you purchased or otherwise acquired Teva Pharmaceutical Industries Ltd. (“Teva”) American Depositary Shares (“ADS”), 7.00% mandatory convertible preferred shares (“Preferred Shares”), and/or certain Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance”) U.S.-dollar-denominated senior notes (“Notes”) during the period from February 6, 2014 through May 10, 2019, inclusive(the “Class Period”), you may be entitled to a payment from a proposed class action settlement.

The Court held a Settlement Hearing on June 2, 2022 and approved the settlement and Plan of Allocation. The Court also granted the motion for the awards of attorneys’ fees, litigation expenses, and reasonable costs and expenses to Class Representatives. The settlement will create a $420 million cash fund, plus earned interest, for the benefit of eligible Settlement Class Members after the deduction of Court-approved fees, expenses, and Taxes, and after deductions for awarded attorneys’ fees and litigation expenses, to pay claims of all persons and entities who purchased or otherwise acquired Teva ADS, Preferred Shares, or Notes during the Class Period.

Submit a Claim

The deadline to submit claims has passed. The Court has entered a Final Bar Date of July 7, 2023, meaning that any claims postmarked or submitted after July 7, 2023 (and purported cures of deficiencies or responses to data integrity review requests received after July 7, 2023), will be rejected without further notice. No extensions will be granted. On September 18, 2023, the Court entered an order authorizing the Reserve Distribution of the Net Settlement Fund.

The Frequently Asked Questions page of this website has more information on your rights as a Settlement Class Member in this Action.

Please do not call the Court or Defendants’ counsel with questions about the Settlement.